Shionogi saw the highest growth of 1.29% in patent filings in April and 1.49% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.29% and grants by 0.46%. GlobalData’s DataBook provides a comprehensive analysis of Shionogi‘s patent filings and grants. Buy the databook here.
Shionogi has been focused on protecting inventions in European Patent Office(EPO) with 13 publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 9% filings and 17% grants. The China(CN), United States(US), Japan(JP), and European Patent Office(EPO) patent Office are among the top ten patent offices where Shionogi is filings its patents. Among the top granted patent authorities, Shionogi has 17% of its grants in European Patent Office(EPO), 17% in Japan(JP) and 11% in China(CN).
Roche and Sanofi could be the strongest competitors for Shionogi
Patents related to rare diseases and addiction lead Shionogi's portfolio
Shionogi has the highest number of patents in rare diseases followed by, addiction and Covid-19. For rare diseases, nearly 58% of patents were filed and 59% of patents were granted in Q2 2024.
Obesity related patents lead Shionogi portfolio followed by arteriosclerosis, and diabetes
Shionogi has highest number of patents in obesity followed by arteriosclerosis, diabetes, hyperlipidemia, and hypertriglyceridemia. For obesity, nearly 17% of patents were filed and 14% of patents were granted in Q2 2024.
For comprehensive analysis of Shionogi's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.